|
Study
|
Geographic locale
|
Study design
|
Sample size(female/male)
|
Age in years (mean ± SD)
|
HCV-RNA, copies/mL (mean ± SD)
|
HCV genotype 1/non-genotype 1
|
HBV-DNA, copies/mL (mea ± SD)
|
ALT, U/L (mean ± SD)
|
IFN plus ribavirin regimen
|
|---|
| | | | | | | | | |
Drugs
|
Course, weeks
|
Follow-up, weeks
|
|---|
|
Yu et al. [35]
|
China
|
Cohort
|
C: 10/40
|
44.9 ± 9.6
|
5.9 ± 1.4log10
|
C: 30/20
|
4.6 ± 0.9log10
|
97 ± 19
|
PegIFN-α2a, ribavirin
|
genotype 1: 48 non-genotype 1: 24
|
24
|
| | | |
M: 9/37
|
46.4 ± 11.3
|
6.3 ± 1.3log10
|
M: 25/21
| |
93 ± 18
| | | |
|
Liu et al. [32]
|
Taiwan
|
Cohort
|
C: 56/105
|
51.1 ± 10.3
|
2.16 ± 3.4 × 106
|
C: 97/64
|
UD-4.22 × 105
|
121.0 ± 85.0
|
PegIFN-α2a, ribavirin
|
genotype 1: 48 non-genotype 1: 24
|
24
|
| | | |
M: 71/89
|
48.9 ± 10.5
|
2.29 ± 4.1 × 105
|
M: 110/50
| |
126.1 ± 81.8
| | | |
|
Chuang et al. [34]
|
Taiwan
|
Cohort
|
C: 11/31
|
45.04 ± 10.7
|
5.38 ± 0.96log10
|
C: 21/21
|
2.64 ± 2.26log10
|
92.1 ± 73.0
|
IFN-α2b
|
24
|
24
|
| | | |
M: 22/62
|
44.9 ± 11.2
|
5.60 ± 0.94log10
|
M: 48/36
| |
141.1 ± 105.5
| | | |
|
Hung et al. [30]
|
Taiwan
|
Cohort
|
C: 14/22
|
48.8 ± 12.6
|
5.80 ± 1.10og10
|
C: 17/19
|
NR
|
125.8 ± 89.3
|
IFN-α2b
|
24
|
24
|
| | | |
M: 28/44
|
48.3 ± 12.0
|
5.80 ± 1.10og10
|
M: 34/38
| |
164.2 ± 139.9
| | | |
|
Liu et al. [36]
|
Taiwan
|
Cohort
|
C: 5/19
|
46.5 ± 13.2
|
2.4 ± 3.1 × 106
|
C: 14/7
|
1.3 ± 2.5 × 103
|
137.0 ± 81.0
|
IFN-α2a
|
24
|
24
|
| | | |
M: 12/18
|
48.5 ± 9.4
|
1.9 ± 2.2 × 106
|
M: 17/13
| |
177.0 ± 192.0
| | | |
- C HBV and HCV coinfection, M HCV mono-infection, NR not reported, UD not detectable by the real-time PCR assay.
